Patent ID: 7094413
Filing Date: 2006-08-22
Classification: A61K,A61P

Abstract:
1. A method for treating an individual infected with HIV, comprising administering to an HIV infected individual a pharmaceutically effective amount of a) an immunomodulatory peptide; and b) at least one anti-retroviral agent; wherein said immunomodulatory peptide is an oligopeptide is selected from the group consisting of: (a) Arg-Leu-Leu-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:10); (b) Arg-Val-Leu-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:11); (c) Arg-Ile-Leu-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:12); (d) Arg-Leu-Val-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:13); (e) Arg-Leu-Ile-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:14); (f) Arg-Leu-Leu-Val-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:15); (g) Arg-Leu-Leu-Ile-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:16); (h) Arg-Leu-Leu-Leu-Arg-Val-Leu-Leu-Gly-Tyr (SEQ ID NO:17); (i) Arg-Leu-Leu-Leu-Arg-Ile-Leu-Leu-Gly-Tyr (SEQ ID NO:18); (j) Arg-Leu-Leu-Leu-Arg-Leu-Val-Leu-Gly-Tyr (SEQ ID NO:19); (k) Arg-Leu-Leu-Leu-Arg-Leu-Ile-Leu-Gly-Tyr (SEQ ID NO:20); (l) Arg-Leu-Leu-Leu-Arg-Leu-Leu-Val-Gly-Tyr (SEQ ID NO:21); (m) Arg-Leu-Leu-Leu-Arg-Leu-Leu-Ile-Gly-Tyr (SEQ ID NO:22); (n) Arg-Trp-Leu-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:23); (o) Arg-Leu-Trp-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:24); (p) Arg-Leu-Leu-Trp-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:25); (q) Arg-Leu-Leu-Leu-Arg-Trp-Leu-Leu-Gly-Tyr (SEQ ID NO:26); (r) Arg-Leu-Leu-Leu-Arg-Leu-Trp-Leu-Gly-Tyr (SEQ ID NO:27); (s) Arg-Leu-Leu-Leu-Arg-Leu-Leu-Trp-Gly-Tyr (SEQ ID NO:28); (t) Arg-Tyr-Leu-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:29); (u) Arg-Leu-Tyr-Leu-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:30); (v) Arg-Leu-Leu-Tyr-Arg-Leu-Leu-Leu-Gly-Tyr (SEQ ID NO:31); (w) Arg-Leu-Leu-Leu-Arg-Tyr-Leu-Leu-Gly-Tyr (SEQ ID NO:32); (x) Arg-Leu-Leu-Leu-Arg-Leu-Tyr-Leu-Gly-Tyr (SEQ ID NO:33); (y) Arg-Leu-Leu-Leu-Arg-Leu-Leu-Tyr-Gly-Tyr (SEQ ID NO:34); and (z) Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO: 1).